Comparing two methods for analyzing pancreatic fluid in patients with a specific type of tumor.

Aspiration of Duodenopancreatic Juice After Secretin Stimulation (ADPJ-secr-) vs Endoscopic Aspiration (EUS-FNA) for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia (IPMN).

This study is testing two different ways to collect pancreatic fluid from patients with a specific type of tumor to see which method gives better information for diagnosis.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 140 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Fundacion Clinic per a la Recerca Biomédica (Academic / other)
• Locations: 1 site (Barcelona)
• Trial ID: NCT05914077 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of aspiration of duodenopancreatic juice after secretin stimulation compared to endoscopic ultrasound-guided fine needle aspiration for molecular analysis of intraductal papillary mucinous neoplasia (IPMN). Participants will undergo one of the two procedures to determine which method provides better diagnostic information. The study aims to improve the understanding and management of IPMN, a type of pancreatic tumor, by analyzing the fluid obtained from the pancreas. This is a Phase 3 interventional trial, indicating it is in the later stages of testing.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 years with a diagnosis of intraductal papillary mucinous neoplasm based on specific imaging and cytological criteria.

Not a fit: Patients without a confirmed diagnosis of intraductal papillary mucinous neoplasm or those who do not meet the inclusion criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate diagnostic methods for patients with intraductal papillary mucinous neoplasia.

How similar studies have performed: While this approach is being evaluated in this trial, similar studies have shown promise in improving diagnostic techniques for pancreatic tumors.

Eligibility criteria

Inclusion Criteria:

1. Be a man or woman over 18 years of age.
2. Willing to comply with the study procedures described in the protocol.
3. Willing and able to give written informed consent.
4. Meet at least one of the following three criteria in relation to the diagnosis or prognosis of IPMN:

   4.1 Diagnosis of IMPN based on evidence of major criteria or existence of at least 2 minor criteria. Major criterion: Typical findings on MRI and/or EUS (single or multiple cysts with clear ductal communication and/or focal or diffuse dilatation # 5 mm in diameter of the main pancreatic duct without apparent obstructive cause). Minor criteria: a) Mucosecretory cells and/or extracellular mucin on cytological examination of intracystic fluid. b) Clear mucoid or filmy appearance of the intracystic fluid. c) Intracystic fluid CEA concentration \>192 ng/mL or intracystic glucose \< 50 mg/dL.

   4.2 IPMN with cysts with a diameter # 10 mm and/or focal or diffuse dilatation of the main pancreatic duct with a diameter # 7 mm requiring EUS-FNA for diagnostic purposes or to assess risk or existence of malignancy following the main clinical practice guidelines.

   4.3 IPMN with indication for surgical resection of the lesion.
5. In case of a woman of childbearing age\*, willing to use highly effective contraception or practice sexual abstinence from the screening visit until one week after undergoing the procedure under study. Highly effective contraceptive methods will include: combined oral, intravaginal or transdermal hormonal contraceptives (containing oestrogens and progestogens) associated with ovulation inhibition; oral, injectable or implantable progestogen-only hormonal contraception associated with ovulation inhibition; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomised partner; and sexual abstinence. 6. If you are a woman of childbearing age, be willing to undergo a urine pregnancy test prior to inclusion in the study.

Exclusion Criteria:

1. History of surgery that prevents endoscopic access to the major duodenal papilla in the case of ADPJ-secr, or to the area of the stomach or intestine from which to perform FNA.
2. History of acute pancreatitis during the 30 days prior to inclusion.
3. Pregnant women, women who may become pregnant during the month prior to inclusion or women who are breastfeeding.
4. Coagulopathy (PT \< 25%, INR \> 1.5, platelets \< 50,000/mL) preventing FNA.
5. Renal failure with GFR \< 30 mL/min or patients on dialysis.
6. Known hypersensitivity to any component of the ChiRhoStim® (human secretin) formulation.
7. Any clinically relevant medical condition that, in the opinion of the investigator, makes the patient unfit to participate in the study (underlying haematological disorders, autoimmune disease, immunodeficiency, gastrointestinal, psychiatric, renal, hepatic and cardiopulmonary disorders).

Where this trial is running

Barcelona

• Hospital Clínic de Barcelona — Barcelona, Spain (Recruiting)

Study contacts

• Study coordinator: Àngels Ginès

Conditions Intraductal Papillary Mucinous Neoplasm of Pancreas